Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839

Exclusion Criteria

• •Any clinically significant or ongoing adverse events, or laboratory abnormalities from DRI13839 that per Investigator judgment would adversely affect the patient's participation in the long-term extension study.
• •Confirmed platelet count below the lower limit of normal at any time during DRI13839.
• •Pregnancy or breast-feeding.
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.